Our R&D applied to health

A patient-driven integrated research 

gaillac chercheur et fiole dans laboratoire
We design and develop innovative solutions in collaboration with partners and health care professionals, constantly drawing our inspiration from nature and plants, always placing the patient at the heart of our research and development.

Pharmaceutical R&D figures


pharma R&D centers in France


people dedicated to pharma R&D


dedicated to pharma R&D in 2018


dedicated to Oncology activities


dedicated to Dermatology activities


dedicated to Consumer Health Care

Our pipeline

Pierre Fabre Group researchers work tirelessly to develop innovative treatments and technologies in the fields of oncology and dermatology.

Discover all our molecules currently in development.

Download the file

Thank you for the interest you give to our publications. Before accessing to our document, please tell us more about you.

Pharmaceutical research areas

Pharmaceutical R&D expertises

Pierre Fabre invests in 4 lines of pharmaceutical research to devise innovative solutions and provide therapeutic solutions for unmet needs.
Our integrated, cross-disciplinary research, from health to beauty, generates value for patients and health care professionals.

Oncology R&D

Cancer is currently the second highest cause of death in the world, despite the immense progress accomplished over the last 30 years by oncology researchers and specialists around the world.

Pierre Fabre has been a player in oncology since 1978 and has solid expertise in cancer of the lung, breast and bladder and more recently melanoma.

Today the Group makes oncology research its R&D priority.

Pierre Fabre brings its expertise in the research and development of molecules to the development of new biological entities and targeted biotherapies. 

We place precision medicine at the heart of our strategy to provide the right treatment for the right patient at the right time by exploiting the synergies of molecular oncology and immunotherapy.
We take advantage of a global approach centered on the patient to strengthen our scientific understanding of the tumor microenvironment and our capacity to supply high-quality biological products based on multiple technological platforms such as monoclonal antibodies and immunoconjugates.  

Dermatology and onco-dermatology R&D

The Pierre Fabre Group's dermatological research employs cross-disciplinary expertise in pharmaceutical and dermo-cosmetics research and development.

Pierre Fabre R&D Dermatology - Skin

Dermatology R&D is the cornerstone which gives meaning to our continuum of activities "from health to beauty”.

The proven expertise of the Pierre Fabre Group in both oncology and dermatology makes onco-dermatology a natural and indispensable area of our R&D.

Today, our onco-dermatology research is centered on:

  • Skin cancers: Melanoma and Basal cell carcinomas
  • Skin lesions: Actinic keratosis


Consumer Health Care R&D

Consumer health care research at Pierre Fabre is above all based on the patient-consumer, to develop new products bringing greater well-being to homes around the world.

The consumer health care research conducted by the Pierre Fabre Group capitalizes on our pharmaceutical drug expertise and the galenic know-how of our dermo-cosmetics activities.

Innovation for family health is not restricted to the discovery of new formulas, it has the mission of bringing additional comfort to the patient-consumer. To achieve this, it works in close collaboration with marketing experts and favors short innovation cycles and the reuse of technologies

Our ambition is therefore to remain at the forefront of the oral health (Elgydium, Inava, etc.), family health (Dexeryl range, Petit Drill, etc.) and natural health (Naturactive) sectors.

Focus on oncology: innovating to build a better future for patients

Today, the scientific expertise of the Pierre Fabre Group is renowned for its monoclonal antibodies and immunoconjugates

This recognition places the company in a position to participate in the targeted biotherapies revolution.

Our ambition is to prioritize the development of new biological entities and targeted biotherapies which play a key role in tumor immunosuppression.

The research work conducted by our experts covers fields in which there are major medical expectations: skin, colon, breast and lung cancers.


cause of global mortality: cancers